| Oct 31 |
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
|
| Oct 22 |
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
|
| Oct 17 |
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials
|
| Oct 17 |
Annovis Bio To Continue Alzheimer's Disease Clinical Trials
|
| Oct 17 |
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug
|
| Oct 15 |
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's
|
| Oct 15 |
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
|
| Oct 3 |
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
|
| Oct 2 |
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
|
| Sep 30 |
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
|
